Clinical Trial Update: Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating whether rosuvastatin can protect against chemotherapy-induced cardiotoxicity in HER2-positive breast cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Cardiotoxicity

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: Tanta University | Conditions: Chemotherapy-induced Cardiotoxicity, Breast Cancer | Phase 3 | Status: COMPLETED